scholarly journals Nonalcoholic fatty liver disease – a growing public health problem

2021 ◽  
Vol 62 (1) ◽  
pp. 1-3
Author(s):  
Ivana Mikolašević ◽  
Tajana Filipec Kanižaj ◽  
Giovanni Targher
Keyword(s):  
Public Health ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Health Problem ◽  
Fatty Liver Disease ◽  
Public Health Problem ◽  
Nonalcoholic Fatty Liver

Metabolic disturbances in non-alcoholic fatty liver disease

2009 ◽  
Vol 116 (7) ◽  
pp. 539-564 ◽  
Author(s):  
Christopher D. Byrne ◽  
Rasaq Olufadi ◽  
Kimberley D. Bruce ◽  
Felino R. Cagampang ◽  
Mohamed H. Ahmed
Keyword(s):  
Public Health ◽  
Liver Disease ◽  
Fatty Liver ◽  
Health Problem ◽  
Fatty Liver Disease ◽  
Public Health Problem ◽  
Alcoholic Fatty Liver ◽  
Increased Risk ◽  
Alcoholic Fatty Liver Disease ◽  
Over Time

NAFLD (non-alcoholic fatty liver disease) refers to a wide spectrum of liver damage, ranging from simple steatosis to NASH (non-alcoholic steatohepatitis), advanced fibrosis and cirrhosis. NAFLD is strongly associated with insulin resistance and is defined by accumulation of liver fat >5% per liver weight in the presence of <10 g of daily alcohol consumption. The exact prevalence of NAFLD is uncertain because of the absence of simple non-invasive diagnostic tests to facilitate an estimate of prevalence. In certain subgroups of patients, such as those with Type 2 diabetes, the prevalence of NAFLD, defined by ultrasound, may be as high as 70%. NASH is an important subgroup within the spectrum of NAFLD that progresses over time with worsening fibrosis and cirrhosis, and is associated with increased risk for cardiovascular disease. It is, therefore, important to understand the pathogenesis of NASH and, in particular, to develop strategies for interventions to treat this condition. Currently, the ‘gold standard’ for the diagnosis of NASH is liver biopsy, and the need to undertake a biopsy has impeded research in subjects in this field. Limited results suggest that the prevalence of NASH could be as high as 11% in the general population, suggesting there is a worsening future public health problem in this field of medicine. With a burgeoning epidemic of diabetes in an aging population, it is likely that the prevalence of NASH will continue to increase over time as both factors are important risk factors for liver fibrosis. The purpose of this review is to: (i) briefly discuss the epidemiology of NAFLD to describe the magnitude of the future potential public health problem; and (ii) to discuss extra- and intra-hepatic mechanisms contributing to the pathogenesis of NAFLD, a better understanding of which may help in the development of novel treatments for this condition.

scholarly journals Comparing Two Strategies for Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Screening

2019 ◽  
Vol 3 (1) ◽  
pp. 01-02
Author(s):  
Mohammad Kabany
Keyword(s):  
Public Health ◽  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Public Health Issue ◽  
Common Cause ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is a growing disease globally. It is strongly related to obesity and insulin resistance. NAFLD poses a public health issue because it may progress to NASH and subsequently to cirrhosis [1]. Currently, NASH cirrhosis is going to be the second most common cause for chronic liver disease in adult patients awaiting transplantation [2]. There is evidence that its prevalence is also increasing in children which creates an urgent need to identify patients with NAFLD and intervene early.

scholarly journals Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?

Molecules ◽  
2020 ◽  
Vol 25 (9) ◽  
pp. 2026 ◽  
Author(s):  
Dominika Maciejewska ◽  
Arleta Drozd ◽  
Karolina Skonieczna-Żydecka ◽  
Marta Skórka-Majewicz ◽  
Karolina Dec ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Liver Tissue ◽  
Fatty Liver Disease ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Nonalcoholic Fatty Liver ◽  
Change Scores ◽  
Potential Biomarker

Nonalcoholic fatty liver disease (NAFLD) is becoming a major public health problem worldwide. The study aimed to evaluate the concentration of eicosanoids in serum and liver tissue during steatosis progression and to assess whether eicosanoid change scores may predict liver tissue remodeling. Thirty six eight-week-old male Sprague Dawley rats were enrolled and sacrificed at different stages of NAFLD. Eicosanoid concentrations, namely lipoxin A4, hydroxyeicosatetraenoic acids (HETE), hydroxyloctadecadienoic acids (HODE), protectin DX, Maresine1, leucotriene B4, prostaglandin E2, and resolvin D1 measurement in serum and liver tissue with Agilent Technologies 1260 liquid chromatography were evaluated. For the liver and serum concentrations of 9-HODE and 13-HODE, the correlations were found to be strong and positive (r > 0.7, p < 0.05). Along with NAFLD progression, HODE concentration significantly increased, and change scores were more abundant in the liver. The moderate positive correlation between liver and serum (r = 0.52, p < 0.05) was also observed for resolvin E1. The eicosanoid concentration decreased during NAFLD progression, but mostly in serum. There were significant correlations between HETE concentrations in liver and serum, but their associations were relatively low and changes the most in liver tissue. Eicosanoids profile, predominantly 9-HODE and 13-HODE, may serve as a potential biomarker for NAFLD development.

Sign in / Sign up

Export Citation Format

Share Document